Industry Insights

31. What ASCO 2025 Means For The Future Of Oncology Trials 6/13/2025

    Review the ASCO 2025 Annual Meeting, highlighting oncology trials and the need for agile, globally capable CRO partners to navigate today’s evolving trial landscape.

32. Hidden Compliance Risks In Start-Up That Could Derail Your Clinical Trial 6/13/2025

    Kulkarni Law Firm Senior Attorney Edye T. Edens explores the risks embedded in clinical trial start-up activities, such as site activation, contract execution, delegation of responsibilities, and cross-border data flows.

33. We Need Regulatory Clarity—Not Complexity In Clinical Trial Technology 6/12/2025

    The current U.S. deregulatory momentum should not diminish compliance standards but instead serve as a call to streamline and modernize regulatory guidance.

34. HTA In Japan: The Glass Remains Half Full (For Now) 6/12/2025

    While Japan's current HTA system is seen as pro-innovation, potential reforms in 2026 could expand its scope, creating uncertainty for manufacturers in one of the world's largest markets.

35. Early Access Program In France: How Much Of An Opportunity Is It? 6/12/2025

    Navigating France’s Early Access Program is more complex than ever. Amid declining approval rates and mandatory data collection, here’s what pharmaceutical companies need to know about the changing landscape.

36. Insights From Pharma 2025: The Impact Of The European Health Data Space (EHDS) Reform On Healthcare Systems 6/12/2025

    Experts explore the revolutionary European Health Data Space, a reform designed to enhance patient data control, streamline care across borders, and unlock new opportunities for medical research.

37. Insights From Pharma 2025: Driving Commercial Success In Pharma: The Role Of Patient Journey Acceleration And Digital Innovation 6/12/2025

    From predictive AI to the European Health Data Space, industry experts discuss how digital transformation is reshaping patient care and creating new pathways for commercial success in pharmaceuticals.

38. Insights From Pharma 2025: Elevating Patient Engagement 6/12/2025

    A significant gap exists between drug development and patient use. Industry veteran Mark Duman explains why listening to patients is the key to closing it and improving health outcomes.

39. Insights From Pharma 2025: Leadership In Pharma – Empowering Change Through Innovative Thinking 6/12/2025

    What does it take to lead in today's evolving pharmaceutical landscape? Insights from Pharma 2025 reveal that empowering teams through trust, experimentation, and a shared purpose is key.

40. Inclusion Of Health-Related Quality Of Life (HRQoL) And Other Patient-Reported Outcomes (PROs) In FDA Labels 6/12/2025

    With a growing emphasis on patient-centric drug development, new research examines how frequently patient-reported outcomes are actually making it onto United States Food and Drug Administration labels.